Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.

Journal of medical virology - 1 Oct 2006

Kobayashi Mariko, Suzuki Fumitaka, Akuta Norio, Suzuki Yoshiyuki, Arase Yasuji, Ikeda Kenji, Hosaka Tetsuya, Sezaki Hitomi, Kobayashi Masahiro, Iwasaki Satomi, Sato Junko, Watahiki Sachiyo, Miyakawa Yuzo, Kumada Hiromitsu

Abstract excerpt

Response to lamivudine treatment longer than 1 year was compared in 15 patients persistently infected with hepatitis B virus (HBV) genotype A, 38 with genotype B, and 449 with genotype C. Patients with genotype A were younger (median age 37 [range 24-49] vs. 47 [24-67] or 44 [18-73], P = 0.015), possessed hepatitis B e antigen (HBeAg) more frequently (73% vs. 21% or 56%, P < 0.001) and HBV DNA in higher levels...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genome, Viral

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Lamivudine

Share to Proportional Hazards Models

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 16927289
DOI: 10.1002/jmv.20701

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.PMID 16927289Read ↗

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.Semantic proximity Read ↗

Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares.Semantic proximity Read ↗

Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.Semantic proximity Read ↗

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.Semantic proximity Read ↗

Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants.Semantic proximity Read ↗

Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.Semantic proximity Read ↗

HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy.Semantic proximity Read ↗

Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.Semantic proximity Read ↗

Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.Semantic proximity Read ↗

Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy.Semantic proximity Read ↗

The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.Semantic proximity Read ↗

Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.